Placeboes Research Foundation (“Placeboes”, “Foundation”, “we”, “our”, or “us”) encourages scientific and technological innovation that advances knowledge, improves health and human experience, and creates responsible solutions to meaningful problems.
This Innovations Policy establishes the principles governing the conception, development, evaluation, protection, translation, collaboration, dissemination, and responsible use of innovations arising from activities undertaken, supported, commissioned, or formally associated with Placeboes Research Foundation.
For the purposes of this Policy, innovation may include scientific methods, conceptual frameworks, technologies, software, algorithms, artificial intelligence systems, digital platforms, devices, processes, methodologies, educational tools, healthcare solutions, information systems, designs, prototypes, and other novel applications of knowledge.
Placeboes regards innovation as more than the production of something new.
An innovation should be evaluated in relation to the problem it addresses, the evidence supporting it, the context in which it will operate, the constraints governing its use, and its potential consequences for individuals, communities, institutions, and society.
Accordingly, Placeboes seeks to pursue innovation that is:
Novelty alone does not establish value, safety, or suitability for use.
Innovation activities governed by this Policy may include:
Different innovations may require different levels of governance according to their maturity, intended use, risk, and potential consequences.
Innovations making scientific, technical, health-related, or performance claims should be supported by evidence appropriate to the nature and maturity of the innovation.
Early-stage concepts and prototypes should be clearly distinguished from validated technologies or established applications.
Placeboes should not knowingly represent exploratory findings, preliminary prototypes, simulations, theoretical possibilities, or proof-of-concept demonstrations as established effectiveness.
Where evidence remains incomplete, uncertainty should be communicated appropriately.
Innovation should begin with a sufficiently clear understanding of the problem being addressed and the context within which a proposed solution is expected to operate.
Where relevant, development should consider:
A technology that functions technically but fails within its intended context should not automatically be regarded as a successful innovation.
Where innovations affect individuals, patients, clinicians, researchers, communities, or other users, their needs, capabilities, limitations, autonomy, safety, and experience should be considered throughout development.
Human-centred design should not be interpreted merely as interface design. It includes consideration of how technologies interact with human judgement, behaviour, institutions, environments, and existing systems of practice.
Innovation activities must comply with the Foundation's Ethics Policy and applicable ethical requirements.
Potential benefits should be considered alongside foreseeable risks, including risks arising from misuse, unintended application, inequitable access, automation, privacy intrusion, inappropriate dependency, technological failure, or displacement of human judgement.
Technological feasibility does not by itself establish ethical desirability.
Ethical reflection should therefore accompany innovation throughout its lifecycle rather than occurring only after development.
Development or evaluation involving human participants, identifiable human data, clinical information, biological materials, behavioural experimentation, or other activities requiring ethical oversight must undergo appropriate ethical review where required.
Prototype status does not exempt an activity from applicable research-ethics obligations.
Participation in testing or evaluation should be voluntary where applicable and governed by appropriate consent, privacy, safety, and data-protection measures.
Innovations intended for healthcare should be developed with particular attention to patient safety, clinical validity, professional responsibility, privacy, usability, and appropriate human oversight.
Research prototypes and investigational systems must not be represented as clinically validated merely because they demonstrate technical functionality.
Where applicable, appropriate clinical evaluation, regulatory authorization, quality assurance, and professional oversight should precede clinical deployment.
Innovation should support rather than improperly displace accountable clinical judgement.
Artificial intelligence, machine learning, automated reasoning, and related computational systems developed or used by Placeboes should be approached with attention to:
AI-generated output should not be treated as independently established scientific or clinical truth merely because it is computationally produced.
AI-related innovation should also comply with the Foundation's AI Use Policy, Data Sharing Policy, and Ethics Policy.
Where appropriate, technological systems should incorporate constraints, safeguards, feedback mechanisms, human oversight, or other mechanisms that limit operation outside intended or acceptable conditions.
The nature and strength of such constraints should be proportionate to the potential consequences of system failure or inappropriate behaviour.
Safety should, where reasonably possible, be considered as a property of system architecture and operation rather than solely as a responsibility imposed upon the end user.
Placeboes recognizes that technologies developed for one population, institution, economy, culture, or infrastructure may not transfer appropriately to another.
Innovations intended for diverse settings should therefore consider local resources, affordability, infrastructure, skills, cultural context, regulatory environment, maintenance requirements, and implementation capacity.
Adaptation to context should preserve essential requirements for scientific integrity, safety, ethics, and quality.
Prototypes may be developed to investigate feasibility, explore concepts, test assumptions, obtain feedback, or generate evidence for subsequent development.
Prototypes should be clearly identified as such where there is a reasonable possibility that users could otherwise interpret them as finished or validated products.
Testing should be proportionate to the risks associated with the prototype and its intended environment.
Innovations should undergo evaluation appropriate to their intended purpose and stage of development.
Depending upon the innovation, evaluation may include:
Validation requirements should reflect the consequences of error. Higher-risk applications require correspondingly stronger evidence and safeguards.
Placeboes supports experimentation and exploration, including approaches that may ultimately prove unsuccessful.
Failure of a scientifically and ethically conducted experiment is not itself a failure of responsible innovation.
However, experimentation should not expose individuals, institutions, communities, or systems to disproportionate or inadequately considered risks merely in pursuit of novelty.
Lessons arising from unsuccessful approaches should, where appropriate, contribute to subsequent scientific and technological development.
Data used in innovation activities should be obtained, processed, stored, analysed, shared, and retained consistently with applicable law, ethical approvals, consent, confidentiality requirements, contractual obligations, and the Foundation's Data Sharing Policy and Privacy Policy.
Access to data for innovation does not automatically confer authorization for unrelated secondary use.
Particular care should be exercised where datasets contain identifiable, sensitive, proprietary, confidential, or potentially re-identifiable information.
Innovations developed through Placeboes activities may generate intellectual property including inventions, patents, copyrights, software, designs, databases, algorithms, know-how, trademarks, methods, and other protectable outputs.
Potentially protectable innovations should be identified and evaluated before public disclosure where disclosure could compromise legitimate intellectual-property protection.
Ownership, inventorship, authorship, licensing, and commercialization should be determined according to applicable law, agreements, funding conditions, institutional arrangements, and actual contributions.
Protection of intellectual property should not be used to misrepresent scientific contribution or deny legitimate recognition to contributors.
Scientific authorship, legal inventorship, software contribution, and ownership are distinct concepts and should not be treated as interchangeable.
Recognition should reflect the nature of the contribution and applicable scientific, legal, contractual, and professional standards.
Individuals should not be designated as inventors or authors merely because of seniority, administrative authority, funding responsibility, or institutional position.
Researchers and developers should disclose potentially significant or protectable innovations through appropriate institutional processes before public presentation, publication, external distribution, or commercial negotiation where necessary.
Such review should not be used unnecessarily to suppress legitimate scientific communication.
Where protection is appropriate, Placeboes should seek to balance timely scientific dissemination with responsible protection of intellectual property.
Placeboes supports appropriate sharing of scientific knowledge, methods, software, resources, and technologies where such sharing advances research, education, collaboration, or societal benefit.
However, openness does not require unrestricted disclosure of information where legitimate considerations relating to participant privacy, confidentiality, safety, intellectual property, contractual commitments, research integrity, security, commercialization, or responsible technology transfer justify proportionate restrictions.
The appropriate model may therefore range from open access to controlled sharing, collaborative access, or formal licensing.
Innovation frequently occurs through collaboration. Before significant co-development begins, collaborators should, where appropriate, establish understandings concerning:
Collaborative arrangements should seek to prevent later ambiguity concerning ownership and contribution.
Innovations may incorporate third-party software, datasets, models, APIs, libraries, devices, designs, open-source components, or other external resources.
Use of such components must respect applicable licences, intellectual-property rights, contractual restrictions, privacy requirements, and security considerations.
Incorporation of an external component does not automatically transfer ownership of that component to Placeboes.
Placeboes may release or use software under open-source licences where appropriate.
Before release, consideration should be given to:
Open-source release should be an intentional governance decision rather than an accidental consequence of publication.
Innovators should consider reasonably foreseeable misuse, unauthorized access, manipulation, security vulnerabilities, and unintended applications of technologies.
The level of assessment should be proportionate to the capabilities and risks of the technology.
Where disclosure of technical details could create material safety, security, privacy, or misuse risks, responsible limitations on dissemination may be appropriate.
Where relevant to an innovation's intended purpose, development should consider whether access, cost, language, infrastructure, disability, geography, socioeconomic conditions, or other contextual factors could systematically exclude intended beneficiaries.
Innovation should not unnecessarily amplify existing disparities.
Where universal accessibility cannot reasonably be achieved, limitations should be recognized rather than obscured.
Where technological development has material environmental implications, reasonable consideration should be given to energy use, materials, waste, lifecycle, infrastructure requirements, and environmental impact.
The appropriate level of assessment should reflect the scale and nature of the innovation.
Placeboes may license, commercialize, transfer, collaborate on, or otherwise enable external use of innovations where doing so supports responsible translation and institutional objectives.
Commercialization decisions may consider:
Commercial value should not override participant rights, research integrity, ethical obligations, or applicable law.
Financial or professional interests arising from an innovation may create actual, potential, or perceived conflicts of interest.
Researchers, developers, evaluators, and decision-makers should disclose material interests where appropriate.
Individuals should not knowingly allow personal financial interests to distort scientific evaluation, safety assessment, procurement, publication, or institutional decision-making.
Conflicts should be managed in accordance with the Foundation's Ethics Policy and applicable governance arrangements.
Public statements concerning innovations should accurately reflect their stage of development and available evidence.
Terms such as prototype, experimental, research use, validated, clinically evaluated, approved, or similar descriptions should be used accurately.
Demonstration of technical feasibility should not be represented as proof of clinical effectiveness, societal benefit, or commercial readiness.
Marketing or promotional communication should not materially exaggerate capabilities or conceal known limitations.
Where an innovation falls within a regulated category, development and deployment should comply with applicable regulatory requirements.
This may include requirements concerning medical devices, software, data protection, artificial intelligence, clinical research, cybersecurity, consumer protection, intellectual property, or other relevant domains.
Research or prototype status does not automatically exempt an activity from applicable regulatory requirements.
Transfer of Placeboes technologies to collaborators, licensees, commercial entities, healthcare institutions, community organizations, or other users should be undertaken through arrangements appropriate to the nature of the technology.
Where appropriate, transfer arrangements may address:
For innovations capable of materially affecting health, safety, privacy, rights, or important institutional processes, responsibility should not necessarily end at deployment.
Where appropriate and feasible, Placeboes or its development partners should consider monitoring:
Significant new risks should prompt appropriate reassessment.
Placeboes may modify, suspend, restrict, or discontinue an innovation where evidence indicates unacceptable safety, ethical, scientific, security, legal, or operational concerns.
Previous investment of time, resources, or institutional reputation should not prevent reconsideration where circumstances materially change.
Significant innovation programmes should maintain documentation appropriate to their stage, complexity, and risk.
This may include records concerning:
Documentation should support accountability without imposing unnecessary administrative burden on low-risk exploratory work.
Placeboes seeks to foster an environment in which scientific curiosity and technological creativity coexist with critical evaluation.
Researchers and innovators should be encouraged to ask not only “Can this be built?” but also:
Responsible innovation requires continuing engagement with these questions throughout development.
This Innovations Policy should be read together with applicable Placeboes governance documents, including the:
Specific research protocols, ethics approvals, collaboration agreements, licences, funding conditions, regulatory requirements, and contractual obligations may impose additional requirements.
Where more specific requirements apply, those requirements govern the relevant activity.
Placeboes Research Foundation may revise this Innovations Policy periodically to reflect developments in science, technology, institutional activities, ethical standards, intellectual-property practices, or applicable legal and regulatory requirements.
Revisions will be published on the Foundation's website together with an updated effective date.
Questions concerning this Innovations Policy, proposed collaborations, technology development, intellectual property, or responsible translation of Placeboes innovations may be directed to:
Placeboes Research Foundation
Email: info@placeboes.org
Website: www.placeboes.org